Feb 17, 2022 / 02:20PM GMT
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies and Devices & Senior Analyst
Good morning, everyone. Thank you for joining us for day 2 of the company fireside chat for the SVB Leerink Global Healthcare Conference. I am Danielle Antalffy. I'm the med tech analyst here at Leerink, and we are very lucky to have with us Boston Scientific. We have Dan Brennan, CFO; and also Lauren Tengler, Head of Investor Relations. So I will just launch right into Q&A. Dan, if that's okay.
Daniel J. Brennan - Boston Scientific Corporation - Executive VP & CFO
Sure.
Questions and Answers:
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies and Devices & Senior AnalystSo let's start with 2022 guidance, the sense is that it did disappoint some, but you have historically tried to be as conservative as possible. Tell me if I'm wrong in characterizing it that way. But can you talk about your approach to arriving at the 2022 sales growth and EPS guidance